Sponsor Deadline
Posted: 4/10/2024

NCCN Request for Proposals (RFP): Quality Improvement in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL)

The National Comprehensive Cancer Network® (NCCN) and AstraZeneca Pharmaceuticals, LP are collaborating to offer a new grant opportunity seeking proposals for quality improvement initiatives in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (CLL/SLL). NCCN has received a $1 Million Dollar research grant from AstraZeneca (hereafter, “Grantor”) to support NCCN Member Institution faculty for the performance of quality improvement initiatives in the management of CLL/SLL. NCCN will serve as the funding organization. Grants are available only to investigators from NCCN Member Institutions.    

Deadline: June 5, 2024

Eligibility Requirements

Open to: NCCN Member Institutions 

Amount Description

• A total of $1 Million Dollars is available for the funding of all projects. • Please see Section 7.0 for details on maximum per project funding amounts. • The intent is to fund individual projects capped at $250,000 (direct and indirect costs) although smaller, lower-cost projects are encouraged. Funding greater than $250,000 will be considered for exceptional proposals with detailed budget justification. • Max,imum indirect (overhead) rate is 25% and must be included in total grant request amount. • Direct funding will include all costs including investigators’ salaries. For example, $80,000 direct costs and $20,000 indirect costs for a total grant of $100,000. Any funds in excess of the limits stipulated in this section for direct funding will require detailed justification and review

Funding Type